How many employees does Tango Therapeutics, Inc. have?

Tango Therapeutics, Inc. reported 137 employees for the fiscal year ending Dec 2025, in the annual report it filed on March 5, 2026. That is down 11.6% from a year earlier.

What is Tango Therapeutics, Inc.'s revenue per employee?

Tango Therapeutics, Inc. brought in $62.4M of revenue in fiscal Dec 2025, which is $455K per employee. That ranks 56 of 108 companies we track in Biotechnology, where the median is $459K.

Where do these numbers come from?

Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Company data

Tango Therapeutics, Inc. employees and revenue per employee

TNGX · Biotechnology · $3.88B market cap

Tango Therapeutics, Inc. had 137 employees at the end of fiscal Dec 2025, down 11.6% from a year earlier. Revenue for the year was $62.4M, up 48.3% from a year earlier, or $455K per employee. Revenue held up or grew while headcount stayed flat or fell.

Employees

137

-11.6% YoY

Revenue

$62.4M

+48.3% YoY

Revenue / employee

$455K

Peer median $459K

Rank in industry

56 of 108

Biotechnology

Headcount against revenue

Both lines start at 100 in the first year we hold, so you can see which one grew faster.

EmployeesRevenueIndexed to 100 in Dec 2020

Hover a year for the numbers.

TNGX employees and revenue by fiscal year
Year ending	Employees	Revenue	Per employee	Staff YoY	Revenue YoY
Dec 2025	137	$62.4M	$455K	-11.6%	+48.3%
Dec 2024	155	$42.1M	$271K	+10.7%	+15.2%
Dec 2023	140	$36.5M	$261K	+27.3%	+46.9%
Dec 2022	110	$24.9M	$226K	+20.9%	-32.9%
Dec 2021	91	$37.0M	$407K	+2175.0%	+383.8%
Dec 2020	4	$7.7M	$1.91M	—	—

Open roles: we have not matched a verified job board for this company yet.

Employees, last six fiscal years

Revenue per employee, last six fiscal years

Tango Therapeutics, Inc. against similar companies

The closest industry peers by revenue, from Biotechnology.

Company	Employees	Revenue	Revenue / employee	Shape
NKTR Nektar Therapeutics	63	$55.2M	$877K	Hiring into decline
ARCT Arcturus Therapeutics Holdings Inc.	106	$67.2M	$634K	Contracting
ENTA Enanta Pharmaceuticals, Inc.	120	$65.3M	$544K	Contracting
TNGX Tango Therapeutics, Inc.	137	$62.4M	$455K	Leaner
VRDN Viridian Therapeutics, Inc.	252	$70.8M	$281K	Efficient growth
KURA Kura Oncology, Inc.	260	$67.5M	$260K	Hiring ahead
NUVB Nuvation Bio Inc.	298	$62.9M	$211K	Efficient growth
VIR Vir Biotechnology, Inc.	367	$68.6M	$187K	Contracting
NTLA Intellia Therapeutics, Inc.	377	$67.7M	$179K	Leaner

Every Healthcare company

Questions about Tango Therapeutics, Inc.

How many employees does Tango Therapeutics, Inc. have?: Tango Therapeutics, Inc. reported 137 employees for the fiscal year ending Dec 2025, in the annual report it filed on March 5, 2026. That is down 11.6% from a year earlier.
What is Tango Therapeutics, Inc.'s revenue per employee?: Tango Therapeutics, Inc. brought in $62.4M of revenue in fiscal Dec 2025, which is $455K per employee. That ranks 56 of 108 companies we track in Biotechnology, where the median is $459K.
Where do these numbers come from?: Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Free game

Think you can pick better than the S&P 500?

Pick 15 stocks, lock them in, and we score them against the index every trading day for ten years. Free, with a public leaderboard.

Enter the challenge

More data

Compare TNGX with the rest of the market

See who earns the most per employee, who is hiring, and who is cutting, across every company we track.

Leaderboard Healthcare

Source: employee counts and revenue as stated in Tango Therapeutics, Inc.'s annual reports (Form 10-K), latest filed March 5, 2026. This is data, not a recommendation to buy or sell TNGX.